4-HO-DET Stats & Data
Cz-74
Homet
4homet
Colour
Ethocin
4hodet
4-hydroxy-det
NPS DataHub
MW232.33
FormulaC14H20N2O
CAS22204-89-3
IUPAC3-(2-diethylaminoethyl)-1H-indol-4-ol
SMILES
CCN(CC)CCc1cnc2cccc(O)c12InChIKey
OHHYMKDBKJPILO-UHFFFAOYSA-N
Chemical Class
Tryptamine
Psychoactive Class
Psychedelic
Receptor Profile
Receptor Actions
Agonists
5-HT2A receptor agonist
5-HT2B receptor agonist
5-HT2C receptor agonist
Inhibitors
Serotonin reuptake inhibitor (low affinity)
Effect Profile
Curated + 18 Reports
Psychedelic
8.8
Strong visuals, headspace, auditory effects, and body load
Visual Intensity×3
10
Headspace Depth×3
10
Auditory Effects×1
10
Body Load / Somatic Effects×1
10
Duration Timeline
Bluelight
Onset
Comeup
Peak
Offset
After Effects
Oral
Total: 3-7 hours
Intravenous
Total: 3-7 hours
Smoked
Total: 3-7 hours
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Full tolerance
1h
Half tolerance
10d
Baseline
~14d
Cross-Tolerances
LSD
80%
●○○
Psilocybin
85%
●○○
Psilocin
85%
●○○
Mescaline
65%
●○○
DMT
85%
●○○
5-MeO-DMT
85%
●○○
2C-B
65%
●○○
2C-E
65%
●○○
Experience Report Analysis
Erowid
18
Reports
2004–2020
Date Range
8
With Age Data
21
Effects Detected
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 18 experience reports (18 Erowid)
18
Reports
21
Effects Detected
9
Positive
5
Adverse
7
Neutral
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 9
Color Enhancement
61.1%
70%
Stimulation
61.1%
70%
Music Enhancement
55.6%
70%
Focus Enhancement
50.0%
70%
Euphoria
44.4%
70%
Introspection
38.9%
70%
Empathy
38.9%
70%
Tactile Enhancement
38.9%
70%
Body High
27.8%
70%
Adverse Effects 5
Confusion
61.1%
70%
Muscle Tension
38.9%
70%
Nausea
27.8%
70%
Anxiety
27.8%
70%
Pupil Dilation
16.7%
70%
Dosage Distribution
Dose distribution from experience reports
Median: 25.0 mg
IQR: 25.0–30.0 mg
n=11
Real-World Dose Distribution
62K DosesFrom 20 individual dose entries
Oral (n=18)
Median: 25.0mg
25th: 25.0mg
75th: 30.0mg
90th: 35.9mg
mg/kg median: 0.394
mg/kg 75th: 0.519
Form / Preparation
Most common forms and preparations reported
Redose Patterns
Redosing behavior across 13 reports
0.0%
Redosed
1.0
Avg Doses
Legal Status
| Country | Status | Notes |
|---|---|---|
| Finland | Scheduled in the "government decree on psychoactive substances banned from the consumer market". | |
| Germany | 4-HO-DET is controlled under Anlage I BtMG ( Narcotics Act, Schedule I ), former: Opiumgesetz ( Opium Act ) as of February 25, 1967. | It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license. |
| Sweden | Sveriges riksdags health ministry Statens folkhälsoinstitut classified 4-HO-DET as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Nov 1, 2005, in their regulation SFS 2005:733 listed as 4-hydroxi-N,N-diethyltryptamin (4-HO-DET), making it illegal to sell or possess. | |
| Switzerland | 4-HO-DET is a controlled substance specifically named under Verzeichnis E. | |
| United Kingdom | 4-HO-DET is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause. | |
| United States | 4-HO-DET is unscheduled in the United States, but purchase, sale, or possession for human consumption could be prosecuted under the Federal Analogue Act. |
References
Cited References
- Bluelight: 4-HO-DET Discussion Thread
- Erowid: 4-HO-DET Experience Vaults
- Hofmann A, Troxler F: Therapeutic Indoles for Psychic Stimulation (US Patent 3072530)
- Isomer Design TiHKAL Entry #16: 4-HO-DET
- Leuner H et al: Psycholytische Therapie nach Hanscarl Leuner - Grundlagen, Praxis, Perspektiven
- Talaie H et al: Dose-independent occurrence of seizure with tramadol (2009)